Avid Bioservices, Inc. - Common Stock (CDMO)

TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today provided notice (the “Notice”) to holders of its 7.00% Convertible Senior Notes due 2029 (the “Notes”), pursuant to the terms of the Indenture, dated as of March 12, 2024 (the “Indenture”), by and between the Company and U.S. Bank Trust Company, National Association (“U.S. Bank”), as trustee, governing the Notes that, in connection with the closing of the transaction contemplated by the Agreement and Plan of Merger, dated as of November 6, 2024 (the “Merger Agreement” and such transaction, the “Merger”), by and among Avid, Space Finco, Inc. and Space Mergerco, Inc., a Fundamental Change and a Make-Whole Fundamental Change (each as defined in the Indenture) occurred under the Indenture on February 5, 2025.

LONDON and BOSTON and TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, and Ampersand Capital Partners (“Ampersand”), a private equity firm specialising in growth equity investments in the life sciences and healthcare sectors, today announced the successful closing of the previously announced acquisition of Avid Bioservices (“Avid” of the “Company”), a dedicated biologics Contract Development and Manufacturing Organisation (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies.

TUSTIN, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQCDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Avid stockholders voted to approve the transaction with GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners (“Ampersand”) at the Avid special meeting of stockholders (the “Special Meeting”) held earlier today.

Mails Letter to Stockholders Highlighting the Significant, Immediate and Certain Cash Value the Transaction Delivers to Stockholders

Leading Independent Proxy Advisory Firms Recognize the Significant, Immediate and Certain Cash Value the Transaction Delivers to Avid Stockholders

Avid Urges Stockholders to Vote FOR the Pending Transaction TODAY

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avid Bioservices, Inc. (NasdaqCM: CDMO) to funds managed by GHO Capital Partners LLP and Ampersand Capital Partners. Under the terms of the proposed transaction, shareholders of Avid will receive $12.50 in cash for each share of Avid that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

NEW YORK, Jan. 05, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

TUSTIN, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQCDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the expiration of the waiting period under the Hart-Scott-Rodino (“HSR”) Antitrust Improvements Act of 1976 with respect to the previously announced agreement for Avid to be acquired by GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners (“Ampersand”).

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQCDMO) to funds managed by GHO Capital Partners LLP and Ampersand Capital Partners for $12.50 per share in cash is fair to Avid shareholders.

Files Definitive Proxy Statement and Mails Letter to Stockholders

LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQCDMO) for potential breaches of fiduciary duty on the part of its directors and management.

LOS ANGELES, CA / ACCESSWIRE / December 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQCDMO) for potential breaches of fiduciary duty on the part of its directors and management.

LOS ANGELES, CA / ACCESSWIRE / December 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQCDMO) for potential breaches of fiduciary duty on the part of its directors and management.

LOS ANGELES, CA / ACCESSWIRE / December 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQCDMO) for potential breaches of fiduciary duty on the part of its directors and management.

LOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. ("Avid" or "the Company") (NASDAQCDMO) for potential breaches of fiduciary duty on the part of its directors and management.

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Avid Bioservices, Inc. (“Avid” or “the Company”) (NASDAQCDMO) for potential breaches of fiduciary duty on the part of its directors and management.

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avid Bioservices, Inc. (NasdaqCM: CDMO) to funds managed by GHO Capital Partners LLP and Ampersand Capital Partners. Under the terms of the proposed transaction, shareholders of Avid will receive $12.50 in cash for each share of Avid that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

NEW YORK, Nov. 09, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Ademi LLP is investigating Avid (NASDAQCDMO) for possible breaches of fiduciary duty and other violations of law in its transaction with GHO and Ampersand.

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQCDMO) to funds managed by GHO Capital Partners LLP and Ampersand Capital Partners for $12.50 per share in cash is fair to Avid shareholders.